A Phase 3 interventional study of Nalmefene hydrochloride and Placebo in Alcohol Dependence, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.
Among the 12 studies testing nalmefene in Alcoholism, this one has the largest enrollment, is one of 4 that started in 2015, is one of 6 in phase 3, and was the 7th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →
nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2015.
This study's enrollment of 678 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 212 across the 12 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 5 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing nalmefene in Alcoholism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol consumption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nalmefene hydrochloride
Drug: Nalmefene hydrochloride
Drug: Placebo
As-needed; tablets, orally
As-needed; tablets, orally
Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12
The number of HDDs is defined as the number of days per month \[days/month\] with alcohol consumption of \> 60 g for males and \> 40 g for females
Time frame: Week 12
Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24
Time frame: Week 24
Change in Total Alcohol Consumption (TAC) From Baseline at Week 12
Time frame: Week 12
Change in Total Alcohol Consumption (TAC) From Baseline at Week 24
Time frame: Week 24
Response Shift Drinking Risk Level (RSDRL) at Week 12
Proportion of patients with a downward shift in drinking risk level of two categories or more
Time frame: Week 12
Response Shift Drinking Risk Level (RSDRL) at Week 24
Proportion of patients with a downward shift in drinking risk level of two categories or more
Time frame: Week 24
Response Low Drinking Risk Level (RLDRL) at Week 12
Proportion of patients with low or lower drinking risk level
Time frame: Week 12
Response Low Drinking Risk Level (RLDRL) at Week 24
Proportion of patients with low or lower drinking risk level
Time frame: Week 24
70% TAC Responder Rate at Week 12
Proportion of patients with a 70% decrease in TAC
Time frame: Week 12
70% TAC Responder Rate at Week 24
Proportion of patients with a 70% decrease in TAC
Time frame: Week 24
HDD Responder Rate at Week 12
Proportion of patients with ≤4 HDDs
Time frame: Week 12
HDD Responder Rate at Week 24
Proportion of patients with ≤4 HDDs
Time frame: Week 24
Change in CGI-S From Baseline at Week 12
The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).
Time frame: Week 12
Change in CGI-S From Baseline at Week 24
The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).
Time frame: Week 24
Change in CGI-I From Baseline at Week 12
The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).
Time frame: Week 12
Change in CGI-I From Baseline at Week 24
The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).
Time frame: Week 24
Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12
All-patients-randomised set
Time frame: Week 12
Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24
All-patients-randomised set
Time frame: Week 24
Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12
All-patients-randomised set
Time frame: Week 12
Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24
All-patients-randomised set
Time frame: Week 24
Safety analysis set, which included all randomized patients who received ≥1 dose of the study medication.
| Milestone | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Started | 248 | 184 | 245 |
| Completed | 189 | 139 | 219 |
| Not completed | 59 | 45 | 26 |
| Withdrew: Withdrawal by subject | 10 | 8 | 9 |
| Withdrew: Adverse event | 45 | 33 | 11 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Physician decision | 3 | 2 | 5 |
| Withdrew: Death | 0 | 1 | 0 |
The number of HDDs is defined as the number of days per month \[days/month\] with alcohol consumption of \> 60 g for males and \> 40 g for females
| days/month | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12 | -12.25 ± 0.64 | -12.09 ± 0.74 | -7.91 ± 0.61 |
| days/month | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24 | -13.25 ± 0.66 | -13.88 ± 0.77 | -9.33 ± 0.63 |
| g/day | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Total Alcohol Consumption (TAC) From Baseline at Week 12 | -44.90 ± 2.01 | -45.36 ± 2.32 | -32.43 ± 1.91 |
| g/day | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Total Alcohol Consumption (TAC) From Baseline at Week 24 | -49.43 ± 2.13 | -49.55 ± 2.45 | -38.28 ± 1.99 |
Proportion of patients with a downward shift in drinking risk level of two categories or more
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Response Shift Drinking Risk Level (RSDRL) at Week 12 | 41.3 | 35.7 | 20.1 |
Proportion of patients with a downward shift in drinking risk level of two categories or more
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Response Shift Drinking Risk Level (RSDRL) at Week 24 | 44.4 | 47.5 | 27.5 |
Proportion of patients with low or lower drinking risk level
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Response Low Drinking Risk Level (RLDRL) at Week 12 | 29.6 | 25.3 | 10.7 |
Proportion of patients with low or lower drinking risk level
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Response Low Drinking Risk Level (RLDRL) at Week 24 | 29.6 | 32.6 | 17.6 |
Proportion of patients with a 70% decrease in TAC
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| 70% TAC Responder Rate at Week 12 | 18.0 | 19.5 | 8.5 |
Proportion of patients with a 70% decrease in TAC
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| 70% TAC Responder Rate at Week 24 | 23.8 | 23.4 | 10.8 |
Proportion of patients with ≤4 HDDs
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| HDD Responder Rate at Week 12 | 35.0 | 36.4 | 19.2 |
Proportion of patients with ≤4 HDDs
| percentage | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| HDD Responder Rate at Week 24 | 33.9 | 44.0 | 25.2 |
The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).
| units on a scale | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in CGI-S From Baseline at Week 12 | -0.60 ± 0.05 | -0.63 ± 0.06 | -0.34 ± 0.05 |
The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).
| units on a scale | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in CGI-S From Baseline at Week 24 | -0.75 ± 0.06 | -0.77 ± 0.07 | -0.41 ± 0.05 |
The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).
| units on a scale | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in CGI-I From Baseline at Week 12 | 2.62 ± 0.07 | 2.65 ± 0.08 | 3.13 ± 0.06 |
The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).
| units on a scale | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in CGI-I From Baseline at Week 24 | 2.49 ± 0.07 | 2.44 ± 0.09 | 2.99 ± 0.07 |
All-patients-randomised set
| IU/L | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12 | 3.666 ± 0.027 | 3.702 ± 0.031 | 3.858 ± 0.025 |
All-patients-randomised set
| IU/L | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24 | 3.663 ± 0.031 | 3.692 ± 0.035 | 3.831 ± 0.028 |
All-patients-randomised set
| IU/L | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12 | 2.968 ± 0.023 | 2.988 ± 0.027 | 3.038 ± 0.021 |
All-patients-randomised set
| IU/L | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24 | 2.971 ± 0.023 | 2.987 ± 0.027 | 3.036 ± 0.021 |
Collected over 24-week treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nalmefene Hydrochloride 20 mg | 0/248 (0%) | 2/248 (0.8%) | 175/248 (70.6%) |
| Nalmefene Hydrochloride 10 mg | 1/184 (0.5%) | 2/184 (1.1%) | 125/184 (67.9%) |
| Placebo | 0/245 (0%) | 2/245 (0.8%) | 127/245 (51.8%) |
| Event | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/248 | 1/184 | 0/245 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/248 | 1/184 | 0/245 |
| Anastomotic ulcer haemorrhageInjury, poisoning and procedural complications | 0/248 | 0/184 | 1/245 |
| AlcoholismPsychiatric disorders | 0/248 | 0/184 | 1/245 |
| Chronic hepatitisHepatobiliary disorders | 1/248 | 0/184 | 0/245 |
| GastroenteritisInfections and infestations | 1/248 | 0/184 | 0/245 |
| Event | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 54/248 | 40/184 | 91/245 |
| NauseaGastrointestinal disorders | 79/248 | 58/184 | 15/245 |
| DizzinessNervous system disorders | 51/248 | 20/184 | 10/245 |
| SomnolenceNervous system disorders | 39/248 | 18/184 | 17/245 |
| VomitingGastrointestinal disorders | 34/248 | 16/184 | 5/245 |
| HeadacheNervous system disorders | 24/248 | 21/184 | 20/245 |
| MalaiseGeneral disorders | 24/248 | 7/184 | 8/245 |
| InsomniaPsychiatric disorders | 20/248 | 15/184 | 2/245 |
| Decreased appetiteMetabolism and nutrition disorders | 13/248 | 11/184 | 3/245 |
| PalpitationsCardiac disorders | 13/248 | 7/184 | 2/245 |
| Age, Categorical(Participants) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 213 | 159 | 217 | 589 |
| >=65 years | 29 | 21 | 27 | 77 |
| Age, Continuous(years) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 48.9 ± 12.2 | 49.2 ± 11.9 | 48.1 ± 11.4 | 48.7 ± 11.8 |
| Sex: Female, Male(Participants) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 72 | 46 | 90 | 208 |
| Male | 170 | 134 | 154 | 458 |
| Region of Enrollment(participants) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 242 | 180 | 244 | 666 |
| Heavy Drinking Days (HDDs)(days/month) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 22.64 ± 6.37 | 23.49 ± 6.07 | 22.97 ± 6.44 | 22.99 ± 6.32 |
| Total Alcohol Consumption (TAC)(g/day) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 93.07 ± 37.45 | 95.93 ± 41.10 | 95.08 ± 48.70 | 94.58 ± 42.79 |
| Drinking Risk Level (DRL)(Participants) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Low | 0 | 0 | 0 | 0 |
| Medium | 0 | 0 | 1 | 1 |
| High | 135 | 93 | 127 | 355 |
| Very high | 107 | 87 | 116 | 310 |
| Clinical Global Impression - Severity of Illness (CGI-S) score(units on a scale) | Nalmefene Hydrochloride 20 mg | Nalmefene Hydrochloride 10 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 3.38 ± 1.06 | 3.48 ± 1.15 | 3.45 ± 1.09 | 3.43 ± 1.09 |
2 further baseline measures are reported on the registry.
Ran from Feb 2015 to primary completion in Jul 2016, 17 months.
Results were first posted in Sep 2019, 3 years 2 months after primary completion.
Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene
Otsuka Pharmaceutical Co., Ltd. →